- Home
- FYBR vs CORT Comparison
FYBR vs CORT Comparison
Compare FYBR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- CORT
- Stock Information
- Founded
- FYBR 1935
- CORT 1998
- Country
- FYBR United States
- CORT United States
- Employees
- FYBR N/A
- CORT N/A
- Industry
- FYBR Telecommunications Equipment
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- FYBR Consumer Discretionary
- CORT Health Care
- Exchange
- FYBR Nasdaq
- CORT Nasdaq
- Market Cap
- FYBR 9.2B
- CORT 7.6B
- IPO Year
- FYBR N/A
- CORT N/A
- Fundamental
- Price
- FYBR $36.94
- CORT $70.33
- Analyst Decision
- FYBR Hold
- CORT Strong Buy
- Analyst Count
- FYBR 5
- CORT 4
- Target Price
- FYBR $38.50
- CORT $138.25
- AVG Volume (30 Days)
- FYBR 2.8M
- CORT 863.6K
- Earning Date
- FYBR 07-29-2025
- CORT 07-31-2025
- Dividend Yield
- FYBR N/A
- CORT N/A
- EPS Growth
- FYBR N/A
- CORT N/A
- EPS
- FYBR N/A
- CORT 1.11
- Revenue
- FYBR $6,045,000,000.00
- CORT $716,080,000.00
- Revenue This Year
- FYBR $5.64
- CORT $35.85
- Revenue Next Year
- FYBR $3.32
- CORT $35.22
- P/E Ratio
- FYBR N/A
- CORT $63.10
- Revenue Growth
- FYBR 4.15
- CORT 25.71
- 52 Week Low
- FYBR $27.67
- CORT $33.34
- 52 Week High
- FYBR $39.21
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- FYBR 56.22
- CORT 47.40
- Support Level
- FYBR $36.85
- CORT $70.05
- Resistance Level
- FYBR $37.16
- CORT $71.28
- Average True Range (ATR)
- FYBR 0.16
- CORT 1.75
- MACD
- FYBR 0.00
- CORT -0.08
- Stochastic Oscillator
- FYBR 64.57
- CORT 19.64
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.